



HHS Public Access

Author manuscript

Cell Rep. Author manuscript; available in PMC 2017 September 14.

Published in final edited form as:

Cell Rep. 2017 September 05; 20(10): 2525. doi:10.1016/j.celrep.2017.08.073.

Dysregulation of miRNA-9 in a Subset of Schizophrenia Patient-Derived Neural Progenitor Cells

Aaron Topol, Shijia Zhu, Brigham J. Hartley, Jane English, Mads E. Hauberg, Ngoc Tran, Chelsea Ann Rittenhouse, Anthony Simone, Douglas M. Ruderfer, Jessica Johnson, Ben Readhead, Yoav Hadas, Peter A. Gochman, Ying-Chih Wang, Hardik Shah, Gerard Cagney, Judith Rapoport, Fred H. Gage, Joel T. Dudley, Pamela Sklar, Manuel Mattheisen, David Cotter, Gang Fang^{*}, and Kristen J. Brennand^{*}

<http://dx.doi.org/10.1016/j.celrep.2017.08.073>

(*Cell Reports* 15, 1024–1036; May 3, 2016)

In the originally published version of this article, the concentration of dual-SMAD inhibitors used was incorrectly reported in the Supplemental Experimental Procedures as “0.1 mM LDN193189 (Stemgent) and 10 mM SB431542 (Tocris)” instead of “0.1 μ M LDN193189 (Stemgent) and 10 μ M SB431542 (Tocris).” The Supplemental Experimental Procedures section has now been corrected online.

The authors regret this error.

^{*}Correspondence: gang.fang@mssm.edu (G.F.), kristen.brennand@mssm.edu (K.J.B.).